Schoos, Mikkel M <br/><br/>
Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial.  [electronic resource] 

 -  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology  Oct 2016 
 - 1144-1153 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1969-6213 
<br/><br/><label>Standard No.: </label>10.4244/EIJV12I9A186  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anticoagulants--therapeutic use<br/>Antithrombins--therapeutic use<br/>Cause of Death<br/>Drug Therapy, Combination<br/>Female<br/>Graft Occlusion, Vascular--epidemiology<br/>Heparin--therapeutic use<br/>Hirudins<br/>Humans<br/>Male<br/>Middle Aged<br/>Mortality<br/>Myocardial Infarction--epidemiology<br/>Myocardial Revascularization--statistics & numerical data<br/>Peptide Fragments--therapeutic use<br/>Percutaneous Coronary Intervention--methods<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Postoperative Complications--epidemiology<br/>Recombinant Proteins--therapeutic use<br/>Recurrence<br/>ST Elevation Myocardial Infarction--therapy<br/>Stroke--epidemiology<br/>Thrombosis--epidemiology<br/>Time-to-Treatment--statistics & numerical data<br/>Treatment Outcome